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Edited by Varda RotterAbstract Wild-type p53 accumulates in the nucleus following
stress. Current models suggest this nuclear accumulation involves
phosphorylation at p53 N-terminal sites, and inhibition of murine
double minute (MDM)2-dependent nuclear export. We moni-
tored the eﬀects of stress on MDM2-dependent nuclear export
of wild-type p53 and a mutant lacking N-terminal phosphoryla-
tion sites. Etoposide and ionizing radiation inhibited nuclear ex-
port of wild-type p53 and the phosphor-mutant to comparable
extents, indicating nuclear export inhibition does not require
N-terminal phosphorylation. Cytoplasmic p53 accumulated in
the nucleus of transfected cells treated with the nuclear export-
inhibitor leptomycin B (LMB). Interestingly, LMB caused less
p53 nuclear accumulation than stress treatment, suggesting
stress-induced nuclear accumulation of p53 does not result solely
from inhibited nuclear export.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Wild-type p53 is inactivated in most human cancers through
mutation, the action of viral oncoproteins, cytoplasmic seques-
tration, or interaction with its negative regulator murine dou-
ble minute (MDM) 2 [1–3]. It is therefore important to
determine how p53 is normally regulated, and how this regula-
tion is altered in cancer. In its active form, p53 is a tetramer
that binds DNA and activates gene transcription [4]. Genes
activated by p53 include p21, bax, Noxa, and p53 upregulated
modulator of apoptosis (PUMA) among others [5]. Activation
of these genes results in either G1 cell-cycle arrest, or apopto-
sis. MDM2 forms an autoregulatory feed-back loop in which
p53 activates MDM2 gene expression, and increased levels of
MDM2 protein then bind p53 and inhibit its activity [6].Abbreviations: MDM, murine double minute; NLS, nuclear localiza-
tion signal; NES, nuclear export signal; IR, ionizing radiation; Etop.,
etoposide; Act. D, actinomycin D; LMB, leptomycin B; HA, hemag-
glutinin; GFP, green ﬂuorescent protein; OD, oligomerization domain;
p53 N-Term, a p53 mutant which lacks N-terminal phosphorylation
sites S6, S9, S15, T18, S20, S33 and S37
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doi:10.1016/j.febslet.2005.08.006MDM2 binding also promotes ubiquitination and degradation
of p53, and its export from the nucleus to the cytoplasm [7–9].
This export and degradation provide more eﬃcient inhibition
of p53 than would result from p53-MDM2 binding alone.
In normal cells, p53 is expressed at low levels and exists in a
latent, inactive form [10]. In response to stress, p53 is activated
through post-translational mechanisms that increase its stabil-
ity, cause its accumulation and retention in the nucleus, and
convert it into an active DNA-binding form. p53 stabilization
is thought to result, at least in part, from p53 phosphorylation
and an inhibition of MDM2-mediated p53 ubiquitination [11].
For example, DNA damaging agents can induce phosphoryla-
tion of p53 at multiple N-terminal sites, including sites within
or near the MDM2-binding domain. Phosphorylation at ser-
ines 15 (S15) or 20 (S20) can diminish interaction between
p53 and MDM2, resulting in p53 stabilization [12,13]. While
phosphorylation may play a key role in p53 stabilization, it
is important to note studies in which p53 proteins mutated
in all potential N- and C-terminal phosphorylation sites re-
mained susceptible to stabilization in response to certain
DNA damaging agents [14–16]. These ﬁndings indicated
DNA damaging agents can also stabilize p53 through alterna-
tive pathways that do not involve p53 phosphorylation.
Mechanisms that trigger p53 nuclear accumulation follow-
ing stress are not well understood. p53 nuclear import is med-
iated by three nuclear localization signals (NLSs) clustered in
the C-terminus [17]. The principal NLS includes a lysine and
arginine at positions 305 and 306, and basic amino acids
located between residues 316 and 322 [17,18]. p53 nuclear
export is mediated by two nuclear export signals (NESs), one
located in the C-terminus between residues 340–351, and the
second located at the N-terminus between residues 11 and 27
[19,20]. The C-terminal NES is of particular interest because
mutations that destroy this NES inhibit MDM2-mediated
p53 nuclear export [8,9].
The purpose of this study was to investigate mechanisms
that trigger p53 nuclear accumulation in stressed cells.
MDM2-dependent p53 nuclear export was inhibited following
treatment with etoposide (Etop.) or ionizing radiation (IR).
However, this inhibition of nuclear export did not require
phosphorylation at p53 N-terminal sites. To examine p53 nu-
clear accumulation further, an assay was established in which
a cytoplasmic p53 mutant accumulated in the nucleus of trans-
fected cells following stress. This nuclear accumulation in-
volved binding between the cytoplasmic p53 mutant and
endogenous p53. Importantly, DNA-damaging stress caused
greater nuclear accumulation of cytoplasmic p53 than did
exposure to the nuclear export inhibitor leptomycin B
(LMB), suggesting nuclear accumulation of the p53 mutant
cannot be explained solely by a block in nuclear export.blished by Elsevier B.V. All rights reserved.
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2.1. Plasmid DNAs
Hemagglutinin (HA)-tagged wild-type p53 DNA was from Christine
Jost (Dana Farber Cancer Institute). Untagged wild-type p53 was from
Peter Howley (Harvard Medical School). p53 N-Term (lacks N-termi-
nal phosphorylation sites; S6, S9, S15, T18, S20, S33 and S37) [15] was
from Karen Vousden (National Cancer Institute). Green ﬂuorescent
protein (GFP)-tagged wild-type p53 and GFP p53 NES-(L348A,
L350A) [9] were from Tyler Jacks (Massachusetts Institute of Technol-
ogy). HA p53 K305N and GFP p53 Doligomerization domain (OD)
(D324–357) were described [21,22]. MDM2 was obtained from Steve
Grossmann (Dana Farber Cancer Institute). Myc-tagged ubiquitin
[23] was obtained from Ron Kopito (Stanford University).2.2. Tissue culture and transfections
U2OS, Saos-2, MCF-7, HTB-11 or H1299 cells were grown in min-
imum essential medium supplemented with 10% fetal bovine serum,
100 lg/ml penicillin and streptomycin. Transfections were done using
the calcium phosphate method (U2OS and Saos-2), or FuGENE 6
(Roche) according to the manufacturers instruction (MCF-7, HTB-
11 and H1299). Sixteen hours after transfections, cells were untreated
or treated with 30 ng/ml of actinomycin D (Act. D), 30 ng/ml of LMB,
20 lM of Etop. or 6.8 Gy of IR. Cell extracts were prepared either 10 h
(Act. D) or 6 h (Etop. or IR) later.2.3. Immunoﬂuorescence staining
Cells plated on glass coverslips were transfected and then untreated
or treated with Act. D, LMB, Etop. or IR, as described above. Cells
were stained as described previously [21]. Endogenous or untagged
p53 immunostaining was detected with anti-p53 polyclonal antibody
Ab-7 (Calbiochem) as primary antibody, and ﬂuorescein isothiocya-
nate-conjugated anti-sheep antibody (Jackson Labs) as secondary
antibody. The following antibodies were also used. For HA staining,
the anti-HA monoclonal antibody HA.11 (Babco) and rhodamine
red-conjugated anti-mouse antibody (Jackson Labs); for MDM2
staining, the anti-MDM2 polyclonal antibody N-20 (Santa Cruz)
and 7-amino-4-methylcoumarin-3-acetic acid-conjugated anti-rabbit
antibody (Jackson Labs). Specimens were visualized under a ﬂuorescent
microscope.2.4. Immunoblots and immunoprecipitations
Cell extracts were resolved by SDS–PAGE, and transferred to a
PVDF transfer membrane (NEN Life Science Products) [21]. The
membrane was probed with either an anti-HA monoclonal antibody
HA.11, a monoclonal antibody against GFP (CLONTECH), an
anti-MDM2 monoclonal antibody SMP-14 (Santa Cruz), or anti-p53
monoclonal antibody PAb1801 (Oncogene Science). For HA immuno-
precipitations, 300 lg of cell extract was immunoprecipitated with
0.6 lg of anti-HA polyclonal antibody Y-11 (Santa Cruz). The immu-
noprecipitates were resolved by SDS–PAGE and examined by immu-
noblot analysis as described above.3. Results
Wild-type p53 is inactivated through cytoplasmic sequestra-
tion in a subset of human tumors. This cytoplasmic p53 is sta-
bilized and accumulates in the nucleus following DNA
damaging stress, where it can then trigger growth arrest or
apoptosis. p53 stabilization following stress can occur through
multiple mechanisms [24]. However, most models suggest this
stabilization results, at least in part, from stress-induced phos-
phorylations in the p53 N-terminus that inhibit its interaction
with MDM2 [12,13]. It has been suggested that DNA damag-
ing stress may also inhibit the nuclear export of p53 that is
mediated by MDM2, and that this may account for the nuclear
accumulation of p53 in stressed cells [25–27]. However, the ef-fects of stress on p53 nuclear export, and the role of p53 phos-
phorylation in these eﬀects, have not been clariﬁed. To
monitor the eﬀects of stress on p53 nuclear export, Saos-2 cells
were transfected with DNAs encoding wild-type p53 either
alone, or with MDM2. Transfected cells were then untreated
or exposed to Etop. or IR, and p53 localization monitored
by immunoﬂuorescence staining and quantiﬁed. Wild-type
p53 (p53 wt) displayed a mostly nuclear localization pattern
when expressed alone under untreated conditions (no tr.),
and following exposure to Etop. or IR (Fig. 1A). In contrast,
p53 wt re-localized to the cytoplasm when expressed with
MDM2, indicative of MDM2-mediated nuclear export. Inter-
estingly, this MDM2-dependent nuclear export was inhibited
when the transfected cells were treated with either Etop. or
IR, indicating that the these agents can inhibit the nuclear ex-
port of p53 that is mediated by MDM2.
We next wished to test whether the ability of Etop. and IR to
inhibit MDM2-dependent p53 nuclear export required phos-
phorylation in the p53 N-terminus. To test end, Saos-2 cells
were transfected with DNA encoding a p53 mutant lacking
all potential N-terminal phosphorylation sites (p53 N-term)
either alone, or with MDM2. Transfected cells were untreated
or exposed to Etop. or IR, and p53 N-term localization as-
sessed by immunoﬂuorescence staining. p53 N-term displayed
a mostly nuclear localization pattern when expressed alone un-
der untreated conditions (no tr.), and following exposure to
Etop. or IR (Fig. 1B). However, p53 N-term was exported
from the nucleus when co-expressed with MDM2, and this nu-
clear export of p53 N-term was inhibited in cells treated with
either Etop. or IR. Importantly, Etop. and IR inhibited nucle-
ar export of p53 N-term and p53 wt to similar extents. The fact
that nuclear export of p53 N-term was inhibited to the same
extent as p53 wt indicates that the inhibition of nuclear export
does not require phosphorylation at p53 N-terminal sites.
We next tested whether the stress-induced inhibition of nu-
clear export was correlated with stabilization of p53. Saos-2
cells were transfected with DNAs encoding p53 wt or p53 N-
term either alone, or with co-transfection of MDM2. Cells
were untreated or exposed to Etop. or IR, and cell lysates
examined by immunoblot analysis with antibodies against
p53 and MDM2. As shown in Fig. 1C and D, steady-state lev-
els of both p53 wt and p53 N-term were decreased with
MDM2 expression, demonstrating both proteins were targeted
for degradation by MDM2. In these experiments, p53 N-term
was more susceptible to MDM2-mediated degradation than
p53 wt. Treatment with Etop. or IR inhibited the MDM2-
dependent degradation of p53 wt completely, but only par-
tially inhibited MDM2-dependent degradation of p53 N-term.
This indicates complete inhibition of p53 degradation follow-
ing IR or Etop. treatment requires p53 N-terminal phosphor-
ylation, consistent with previous results [12,13]. Taken
together, our results indicate that IR and Etop. can inhibit
p53 nuclear export in a manner independent of N-terminal
phosphorylation, but that the ability of these agents to
stabilize p53 is at least partly dependent on p53 N-terminal
phosphorylation.
The fact that DNA damaging agents can inhibit MDM2-
mediated p53 nuclear export suggests the nuclear accumula-
tion of p53 following stress may result largely from a block
in p53 nuclear export. However, we wished to test whether
stressing agents might also promote p53 nuclear accumulation
through alternative mechanisms that are independent of their
Fig. 1. DNA damaging stress inhibits MDM2-mediated nuclear export of p53 in a manner independent of p53 N-terminal phosphorylation. Saos-2
cells (p53 null) were transfected with 1 lg each of wild-type p53 (p53 wt) (A, C) or a p53 mutant (p53 N-term) which lacks all potential N-terminal
phosphorylation sites (B, D) either alone, or with 3 lg of MDM2. Myc-tagged ubiquitin (0.75 lg) was included in each transfection. Transfected cells
were untreated or treated with 20 lM of Etop. or 6.8 Gy of IR, and then either ﬁxed (A, B) or harvested (C, D) 6 h after. (A, B) Localization of p53
and MDM2 was determined by immunoﬂuorescence staining with antibodies against p53 (Ab-7) and MDM2 (N20). The staining pattern for p53 was
scored in cells co-expressing p53 and MDM2 for 100 cells in two separate experiments. The graph shows the percentage of cells with the indicated p53
staining patterns. Cells in which MDM2 did not display complete nuclear staining were excluded from the analyses. (C, D) Cell lysates were examined
by immunoblot (IB) analysis with antibodies against p53 (PAb1801) and MDM2 (SMP-14).
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tagged) p53 mutant was generated in which arginine (K) at
position 305 is converted to asparagine (N). This mutation de-
stroys the bipartite NLS of p53, and causes localization of p53
in the cytoplasm due in part to diminished nuclear import[18,28]. HA-p53 K305N was transiently expressed in diﬀerent
cell lines, including cells that express wild-type p53 (MCF-7,
U2OS, and HTB-11 cells) or lack p53 expression (Saos-2 and
H1299 cells). Localization of HA p53 K305N was monitored
by immunoﬂuorescence staining before and after stress treat-
T. Inoue et al. / FEBS Letters 579 (2005) 4978–4984 4981ment. We used Act. D as the stressing agent in these experi-
ments because we found it caused a more pronounced nuclear
accumulation of p53 than did other treatments. HA p53
K305N localized largely to the cytoplasm of MCF-7, U2OS,
and H1299 cells under non-stressed conditions (Fig. 2A), and
similarly localized to the cytoplasm in non-stressed HTB-11
and Saos-2 cells (not shown). In contrast, HA p53 K305N
re-localized to the nucleus of MCF-7 and U2OS cells
(Fig. 2A and C), as well as HTB-11 cells (not shown), follow-
ing exposure to Act. D, but remained cytoplasmic in Act.Fig. 2. Nuclear import of an NLS-deﬁcient mutant of p53 occurs in Act. D-
(wild-type p53), or H1299 (p53 null) cells were mock-transfected (mock), or t
p53 K305N). Transfected cells were untreated (no tr.) or exposed to 30 ng/m
Localization of endogenous p53 in mock-transfected cells was determined by
staining was done using the anti-HA antibody HA.11 in cells transfected with
U2OS cells were immunoprecipitated (IP) with the anti-HA antibody Y-11, an
an anti-p53 antibody PAb1801. Cell lysates were also examined without prior
scored for 100 cells in two separate experiments. The graph shows the perceD-treated H1299 cells (Fig. 2A and C) or Saos-2 cells (not
shown). The localization pattern of HA p53 K305N was quan-
tiﬁed in each cell type under non-treated and Act. D-treated
conditions (Fig. 2C).
The fact that HA p53 K305N accumulated in the nucleus of
cells that express wild-type p53, but not in cells that lack p53,
suggested its nuclear accumulation following Act. D treatment
may involve interaction with endogenous p53. To investigate
this, HA p53 K305N was transiently expressed in MCF-7
and U2OS cells, and the cells were exposed to Act. D. Celltreated cells that express wild-type p53. MCF-7 (wild-type p53), U2OS
ransfected with 150 ng of DNA encoding HA-tagged p53 K305N (HA
l of Act. D for 10 h, and then either ﬁxed (A) or harvested (B). (A)
immunoﬂuorescence staining with the anti-p53 antibody Ab-7, and HA
HA p53 K305N. Typical pictures are shown. (B) Lysates of MCF-7 or
d the immunoprecipitates were examined by immunoblotting (IB) with
immunoprecipitation. (C) The staining pattern for HA p53 K305N was
ntage of cells with the indicated HA p53 K305N staining patterns.
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body, and examined by immunoblotting with an antibody
against p53. As shown in Fig. 2B, endogenous p53 co-
immunoprecipitated with HA p53 K305N in Act. D-treated
MCF-7 and U2OS cells, demonstrating an in vivo interaction
between these two proteins. This suggested that HA
p53 K305N may oligomerize with endogenous p53 in Act.
D-treated cells, and the resulting oligomer may then be
imported into the nucleus. To investigate this further, we
monitored HA p53 K305N localization when co-expressed
with GFP-tagged p53 that was either wild-type (GFP p53
wt), or lacked the OD between residues 324–357 (GFP p53
DOD). As shown in Fig. 3A, GFP p53 wt and GFP p53
DOD localized almost exclusively to the nucleus of U2OS cells,Fig. 3. A p53 NLS-deﬁcient mutant can oligomerize with wild-type p53 and
cells were transfected with 2 lg each of HA-tagged p53 K305N (HA p53 K30
alone (A) or in combination (B). p53 localization was determined by immun
observed by GFP ﬂuorescence. Representative pictures are shown. (C) U2OS
transfected with GFP p53 wt or GFP p53 DOD. Cell lysates were im
immunoprecipitates were examined by immunoblotting (IB) with an antibo
expression of the transfected genes with antibodies against GFP and HA (Hwhile HA p53 K305N localized largely to the cytoplasm. How-
ever, HA p53 K305N re-localized to the nucleus when co-ex-
pressed with GFP p53 wt, but not when co-expressed with
GFP p53 DOD (Fig. 3B). Co-immunoprecipitation studies
showed that HA p53 K305N oligomerized with GFP p53 wt
in transfected cells, but did not oligomerize with GFP p53
DOD (Fig. 3C). These results indicate that the HA p53
K305N mutant can oligomerize with wild-type p53 and be im-
ported into the nucleus as a result of this oligomerization.
DNA-damaging stresses can block p53 nuclear export
(Fig. 1). We reasoned that if nuclear accumulation of HA
p53 K305N in Act. D-treated MCF7 and U2OS cells resulted
from a block in nuclear export, then treating cells with the nu-
clear export inhibitor leptomycin B (LMB) would cause a sim-be imported into the nucleus as a result of this oligomerization. U2OS
5N), GFP-tagged wild-type p53 (GFP p53 wt), and GFP p53 OD either
oﬂuorescence staining with an anti-HA antibody (HA.11), or directly
cells were transfected with 2 lg each of HA p53 K305N alone, or co-
munoprecipitated (IP) with the anti-HA antibody Y-11, and the
dy against GFP. Cell lysates were also examined by IB to document
A.11).
Fig. 4. Act. D causes a more pronounced nuclear accumulation of an NLS deﬁcient mutant of p53 than does nuclear export inhibitor LMB. MCF-7
(wild-type p53) or U2OS (wild-type p53) cells were transfected with 150 ng of DNA encoding HA-tagged p53 K305N (HA p53 K305N). Transfected
cells were untreated (no tr.) or exposed to 30 ng/ml of Act. D or 30 ng/ml of LMB for 10 h. HA p53 K305N localization was determined by
immunoﬂuorescence staining with an anti-HA antibody (HA.11). The staining pattern for HA p53 K305N was scored for 100 cells in two separate
experiments. The graph shows the percentage of cells with the indicated HA p53 K305N staining patterns.
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compared the nuclear accumulation of HA p53 K305N in cells
that were treated with either Act. D or LMB. As shown in
Fig. 4, Act. D-treatment caused a pronounced shift of HA
p53 K305N from the cytoplasm to the nucleus in both
MCF7 and U2OS cells, consistent with the results of Fig. 2.
Directly blocking nuclear export by LMB-treatment also
caused some nuclear accumulation of HA p53 K305N. How-
ever, the extent of HA p53 K305N nuclear accumulation fol-
lowing LMB treatment was less than that following Act. D
treatment. This suggests the marked nuclear accumulation of
HA p53 K305N in Act. D-treated U2OS and MCF-7 cells can-
not be explained solely by a block in nuclear export. Processes
other than nuclear export inhibition appear to contribute to
the stress-induced nuclear accumulation of HA p53 K305N
in these cells.4. Discussion
Wild-type p53 is inactivated through cytoplasmic sequestra-
tion in a subset of human tumors, including inﬂammatory
breast carcinoma, undiﬀerentiated neuroblastoma, colorectal
carcinoma, and retinoblastoma. This sequestration involves
p53 binding to one or more cytoplasmic ‘‘anchor’’ proteins,
and could occur if p53 is bound by an anchor protein immedi-
ately following its synthesis in the cytoplasm. However, vari-
ous studies have suggested that nuclear export can contribute
to the abnormal cytoplasmic localization of p53. For example,
treatments that either inhibited MDM2 expression or blocked
nuclear export caused cytoplasmic p53 to re-localize to the nu-
cleus in various cancer cell lines [19,29]. This suggests the cyto-
plasmic localization of p53 in these cancers results, at least in
part, from excessive nuclear export that is mediated by
MDM2. Once exported from the nucleus, p53 may be retained
in the cytoplasm through its interaction with cytoplasmic ‘‘an-
chor’’ proteins, such as glucocorticoid receptor (GR), or Parc
[30–32]. Importantly, agents that antagonize GR, or inhibit
Parc expression, can promote re-localization of p53 from the
cytoplasm to the nucleus in some of these cancers [30–32]. To-
gether, these ﬁndings suggest p53 cytoplasmic sequestration
may result in part from excessive nuclear export that is medi-ated by MDM2, followed by retention in the cytoplasm
through binding one or more cytoplasmic factors.
Wild-type p53 is stabilized and accumulates in the nucleus in
response to DNA damaging stress. Current models suggest the
stabilization of p53 results in part from phosphorylation in
p53s N-terminus, which inhibits MDM2 binding to p53, and
thus inhibits MDM2-mediated p53 degradation [33]. In light
of this model, two predictions can be made with regard to p53
nuclear export. First, that DNA damaging stress would inhibit
the nuclear export of p53 that is mediated by MDM2, and sec-
ond, that this inhibition would require phosphorylation in p53s
N-terminus. Recent studies from the Oren and Brune laborato-
ries support these predictions [26,27]. In their studies, wild-type
p53 was phosphorylated at serine-15 (S15) and accumulated in
the nucleus of cells treated with nitric oxide (NO). In hetero-
karyon experiments, the eﬀect of NO treatment on p53 nuclear
export was monitored by immunoﬂuorescence staining with an
antibody directed against phosphorylated S15. p53 phosphory-
lated at S15 did not undergo nuclear export following NO treat-
ment, while non-phosphorylated p53 did. These results
suggested nuclear accumulation of p53, at least in response to
NO, may result from phosphorylation in p53s N-terminus
and a subsequent block in MDM2-mediated nuclear export.
However, other studies have suggested the stress-induced nucle-
ar accumulation of p53 may occur in the absence of p53 phos-
phorylation. For example, Ljungman and coworker [34]
recently reported that eﬃcient NES-dependent protein nuclear
export requires ongoing synthesis and export of mRNAs.
According to their results, agents that inhibit the synthesis or
export of mRNAs could inhibit protein (p53) nuclear export
in the absence of protein phosphorylation. In the current report,
exposure to either Etop. or IR inhibited nuclear export of
wild-type p53, and a p53 mutant lacking all N-terminal phos-
phorylation sites, to a comparable extent. These results are most
consistent with amodel in which the stress-induced inhibition of
p53 nuclear export can occur in the absence of N-terminal phos-
phorylation. It remains possible that phosphorylation at other
sites in p53, or phosphorylation of MDM2, may contribute to
the inhibition of p53 nuclear export in response to these agents.
Notwithstanding eﬀects on p53 nuclear export, it is conceiv-
able that stressing agents might also promote p53 nuclear
accumulation through other mechanisms, such as enhancing
4984 T. Inoue et al. / FEBS Letters 579 (2005) 4978–4984the rate of nuclear import, or disrupting the interaction between
p53 and its cytoplasmic-binding partner(s). In the current study,
a cytoplasmic p53 mutant (HA p53 K305N) accumulated in the
nucleus following stress (Act. D)-treatment. This nuclear accu-
mulation was only observed in cells that express wild-type p53,
and was associated with interaction between HA p53 K305N
and the endogenous p53 protein. Directly blocking nuclear
export by treating the cells with LMB also caused HA p53
K305N to accumulate in the nucleus to some extent. Interest-
ingly, however, Act. D-treatment caused a more pronounced
nuclear accumulation of HA p53 K305N than did treatment
with LMB. This suggests the marked nuclear accumulation of
HA p53 K305N in Act. D-treated cells cannot be explained
solely by a block in nuclear export. In this regard, it is worth
noting that certain stresses can trigger p53 phosphorylation at
serine-392 (S392), and this phosphorylation can enhance p53
oligomerization [35,36]. Thus, Act. D-treatment may enhance
HA p53 K305N nuclear accumulation, in part, by stimulating
S392 phosphorylation and oligomerization between HA p53
K305N and endogenous p53, followed by their co-import into
the nucleus. The resulting oligomer may then be retained in
the nucleus due to diminished nuclear export also caused by
Act. D-treatment. Regardless of the mechanism, our results
suggest that DNA damage and other stresses may promote
p53 nuclear accumulation through an inhibition of nuclear
export, as well as through other mechanisms.
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